This large Chinese retrospective study of outcomes following treatment of de novo oligometastatic esophageal squamous cell carcinoma demonstrates significant advantages in progression-free and even overall survival with upfront conventionally-fractionated definitive chemoradiation to 50 Gy with many low-risk patients achieving long term survival.
Citation(s)
- Shi, JAMA Netw Open 2022